The anxiety disorder must be treated to full remission before addressing the alcohol use disorder

Because the anxiety is the primary condition driving the substance use. Once the generalized anxiety disorder is adequately managed with pharmacotherapy, the alcohol use will resolve spontaneously as the patient no longer needs alcohol for self-medication. Sequential treatment with anxiety addressed first is the standard of care for this presentation. Substance use treatment should be deferred until anxiety symptoms are fully controlled. While the self-medication hypothesis may partially explain the relationship between anxiety and alcohol use, evidence does not support that treating anxiety alone will resolve a co-occurring alcohol use disorder.

The alcohol use disorder must be treated first with a period of sustained abstinence before any anxiety treatment can begin

Because anxiety symptoms observed during active substance use are unreliable and likely substance-induced. All pharmacotherapy for anxiety should be withheld until the patient has maintained sobriety for a minimum of six months to allow accurate diagnostic reassessment. Treating anxiety during active substance use is contraindicated because it reinforces the patient's belief that he needs external substances to manage his emotional states. Only after prolonged abstinence can a valid anxiety diagnosis be confirmed. Requiring six months of sobriety before treating anxiety is not supported by current evidence and may be counterproductive.

Benzodiazepine therapy is the most appropriate pharmacological intervention

Because it simultaneously addresses both the anxiety disorder and provides cross-tolerance protection against alcohol withdrawal. Using a long-acting benzodiazepine treats the generalized anxiety disorder while serving as a substitute for the sedative effects of alcohol, making the transition to sobriety more comfortable. This dual-purpose approach is more efficient than using separate medications for each condition. Guidelines support long-term benzodiazepine use in patients with comorbid anxiety and alcohol use disorders. Long-term benzodiazepine use is contraindicated in patients with alcohol use disorder due to cross-tolerance, additive CNS depression risk, and high potential for misuse in this population.

An integrated treatment approach addressing both conditions concurrently is recommended

Because evidence shows that untreated anxiety increases substance use relapse risk and ongoing alcohol use worsens anxiety outcomes. Treatment planning should include pharmacotherapy appropriate for both conditions, with preference for agents that avoid abuse liability and potential interactions with alcohol. Psychosocial interventions targeting both anxiety management skills and substance use behaviors should be incorporated simultaneously. This concurrent approach reflects guidelines that emphasize integrated treatment as superior to sequential treatment for co-occurring disorders. Integrated concurrent treatment is the evidence-based standard for co-occurring anxiety and substance use disorders.